Extended Data Fig. 9: 2nd-gen TKIs confer durable clinical benefit in patients with acquired osimertinib-resistant NSCLC. | Nature

Extended Data Fig. 9: 2nd-gen TKIs confer durable clinical benefit in patients with acquired osimertinib-resistant NSCLC.

From: Structure-based classification predicts drug response in EGFR-mutant NSCLC

Extended Data Fig. 9

a, Representative CT images from a patient after 5.5 months  of osimertinib and 6 months after afatinib treatment. Red arrow indicates lesion harboring L858R/L718V. b, CT scan of a patient after 17 months of osimertinib treatment showed new pleural lesion that tested positive for both EGFR L858R and L718V mutations (red arrow), and CT image of patient four weeks after beginning poziotinib treatment shows reduction in size of the pleural lesion (red arrow). Blue arrow indicates resolved pleural effusion. a, b, Schematic below CT images shows timeline of patient treatments and outcomes. c, Schematic representations of a patient treatments and outcomes that acquired two PACC mutations (V765L and C797S) after 18 months of osimertinib treatment. PR = partial response, PD = progressive disease, SD = stable disease, SRS = stereotactic radiosurgery Chemo/IO = carboplatin/ pemetrexed+ pembrolizumab.

Back to article page